Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib
- Status
- WITHDRAWN
- Phase
- PHASE1
Clinical Trials Related to Metastatic Melanoma
Related studies linked through entity extraction aliases.
Vemurafenib and TIL Therapy for Metastatic Melanoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of Molecular Mechanisms Implicated in the Pathogenesis of Melanoma. Role of Exosomes
- Status
- COMPLETED
- Phase
- NA
Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma
- Status
- COMPLETED
- Phase
- PHASE3
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Translational Systems Medicine Approach to Provide Predictive Capacity for Therapy Response in Advanced or Metastatic Malignant Melanoma
- Status
- COMPLETED
- Phase
- N/A
Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery
- Status
- COMPLETED
- Phase
- PHASE2
Interleukin-2-Induced Cognitive/Affective/Sleep Symptoms
- Status
- COMPLETED
- Phase
- N/A
Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma
- Status
- UNKNOWN
- Phase
- PHASE2
Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma
- Status
- COMPLETED
- Phase
- PHASE1
Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma
- Status
- COMPLETED
- Phase
- PHASE1
Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery
- Status
- TERMINATED
- Phase
- PHASE2
Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
- Status
- TERMINATED
- Phase
- PHASE1
Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma
- Status
- TERMINATED
- Phase
- PHASE2